HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics projects HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), announced plans to acquire a network of interventional psychiatry clinics, focusing on ketamine treatments. The acquisition and financing agreements, valued at $30 million, are backed by a qualified lender. The company signed a non-binding Term Sheet for five operational clinics in the Western United States, generating over $10 million in annual revenue.
NRx藥品公司的子公司HOPE Therapeutics, Inc. (NASDAQ:NRXP) 宣佈計劃收購一家側重於低氣溫療法的精神科干預診所網絡。該收購和融資協議總值3000萬美元，由一家合格的借款人提供支持。該公司與一家位於美國西部的運營診所簽訂了一份非約束性期限協議表，年收入超過1000萬美元。
The clinics will focus on treating conditions like suicidal depression, treatment-resistant depression (TRD), and PTSD. HOPE Therapeutics aims to create a unified, patient-centered approach, combining pharmaceutical therapies and FDA-approved technologies like Transcranial Magnetic Stimulation (TMS).
這些診所將側重於治療自殺性抑鬱症、難治性抑鬱症(TRD)和PTSD等疾病。HOPE Therapeutics旨在創建一個統一的、以患者爲中心的方法，將藥物療法和FDA批准的技術(如經顱磁刺激)相結合。
Co-CEOs Jonathan Javitt and Matthew Duffy emphasized the importance of this initiative. "We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care."
聯席首席執行官Jonathan Javitt和Matthew Duffy強調了這項計劃的重要性。「我們很高興邁出發展網絡診所的關鍵第一步，以提供最高水平的護理。」
HOPE Therapeutics projects annualized revenues of $100 million by mid-2025 through continued clinic acquisitions and anticipates potential operations in the United States, France, and the United Kingdom.
HOPE Therapeutics預計到2025年中期實現年收入1億美元，並通過繼續收購診所來擴大業務，並預計在美國、法國和英國進行潛在的運營。
Read Also: The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
閱讀更多：Ketamir-2的潛力：用於精神健康障礙和神經病痛的更安全治療，預計在年底前提交IND申請
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
免費訂閱我們的新聞簡報以獲得Benzinga對大麻行業和市場的獨家分析和頭條新聞。如果你對這個行業很認真，不能錯過。
Ketamine Clinics And Treatments
氯胺酮診所和治療
Ketamine, originally an anesthetic, has gained significant attention in recent years for its off-label use in treating mental health conditions such as depression, PTSD, and treatment-resistant depression (TRD). The rise in ketamine assisted therapies is largely due to its rapid-acting properties, which offer relief where traditional antidepressants often fall short. As research progresses, treatments are becoming more refined, with new delivery methods like nasal sprays, topical creams and patient-controlled infusions enhancing accessibility and effectiveness.
氯胺酮起初是一種麻醉劑，近年來因其在治療抑鬱症、PTSD和難治性抑鬱症(TRD)等精神健康狀況方面的非標籤使用而引起了廣泛關注。氯胺酮輔助療法的興起主要歸功於其快速作用的特性，能在傳統抗抑鬱藥物效果不佳時提供緩解。隨着研究的進展，治療方法變得更加精細，新的給藥方法如鼻噴劑、局部藥膏和患者控制的輸注等提高了可及性和有效性。
Photo: Courtesy of Sonis Photography via Shutterstock
圖片：由 shutterstock 提供的 Sonis Photography 公司的圖像。